Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)
This study is currently recruiting participants.
Study NCT00708162
Information provided by Gilead Sciences
First Received: June 30, 2008
Last Updated: November 10, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
